Perimenopause Socioeconomic Impact: Costs, Productivity, and the Case for Early Treatment

The Scale of the Problem: How Much Does Perimenopause Cost Society?

Perimenopause generates a large and largely hidden economic burden. A landmark 2023 study from the Mayo Clinic (N=4,440 employed women) found that menopause-related symptoms cost U.S. Employers an estimated $1.8 billion per year in lost working time, with vasomotor symptoms, sleep disturbance, and mood changes driving the largest share of that loss [1]. The same study found that 13.4% of women reported reducing work hours specifically because of symptoms, and 10.9% left a job entirely.

Why the Numbers Are Probably an Undercount

Most economic analyses of perimenopause rely on self-reported productivity surveys, which tend to underestimate true costs. Presenteeism, showing up to work but functioning at reduced capacity, is harder to measure than absenteeism. A BMJ Open analysis published in 2022 found that presenteeism accounted for more than 70% of total menopause-related productivity loss in a UK cohort of 3,040 women [2]. Direct costs such as clinic visits, prescription fills, and diagnostic testing are captured more reliably, but they exclude over-the-counter spending on supplements and non-prescription products.

Geographic and Racial Disparities Widen the Gap

Black and Hispanic women experience longer and more severe vasomotor symptom trajectories than white women, according to the Study of Women's Health Across the Nation (SWAN), which followed 3,302 women over 17 years [3]. Those longer symptom durations translate directly into longer periods of economic vulnerability. Black women in SWAN reported hot flashes persisting a median of 10.1 years versus 6.5 years in white women, a difference with clear implications for cumulative productivity loss and healthcare spending.

Vasomotor Symptoms as the Primary Driver of Work Impairment

Vasomotor symptoms (VMS), meaning hot flashes and night sweats, are the symptoms most consistently linked to work performance problems. They affect 60 to 80% of women during the menopausal transition and peak in severity during perimenopause rather than after the final menstrual period [4].

Absenteeism Data

The 2023 Mayo Clinic study found that women with moderate-to-severe VMS missed an average of 3.1 days of work per year due to symptoms [1]. Scaling that figure across the estimated 15.5 million women currently in the perimenopausal transition in the United States suggests tens of millions of lost workdays annually.

Sleep Disruption as a Mediating Factor

Night sweats directly disrupt sleep architecture. A 2019 study published in Menopause (N=1,881) found that perimenopausal women with moderate-to-severe sleep disturbance scored 23% lower on cognitive performance tests compared to asymptomatic women of the same age [5]. Disrupted sleep compounds the direct effect of VMS on concentration, decision-making, and interpersonal function at work.

Mood and Cognitive Symptoms Add a Second Layer

Depression and anxiety are significantly more prevalent during perimenopause than in premenopausal years. A large prospective cohort study published in JAMA Psychiatry (N=1,054) found that women were twice as likely to experience a major depressive episode during perimenopause than in the years before the transition, independent of prior depression history [6]. Cognitive difficulties, often described as "brain fog," affect an estimated 60% of women in perimenopause according to data from the Penn Ovarian Aging Study [7]. Both depression and cognitive symptoms have direct effects on job performance and career progression.

Direct Healthcare Costs During the Perimenopausal Transition

Women in perimenopause use healthcare resources at substantially higher rates than premenopausal women of similar age. A 2021 claims analysis of 276,000 commercially insured U.S. Women published in the Journal of Women's Health found that per-member-per-year spending rose by 56% in the two years surrounding the menopausal transition compared to the two years before it [8].

What Drives the Spending Spike

The largest cost categories were:

• Outpatient office visits, up 48% during perimenopause
• Prescription drug spending, up 63%, driven largely by antidepressants, sleep aids, and hormone therapies
• Emergency department visits for palpitations, anxiety, and unexplained symptoms, up 22%

Many perimenopausal symptoms, including palpitations, urinary urgency, and mood changes, mimic or overlap with other conditions. That overlap generates diagnostic workups for cardiac disease, thyroid dysfunction, and psychiatric disorders that can be expensive and, in some cases, avoidable with timely recognition of perimenopause.

The Delayed-Diagnosis Penalty

A 2022 survey of 1,013 U.S. Women conducted by the Menopause Society found that women waited an average of 2.5 years from symptom onset to receiving a formal diagnosis or treatment plan [9]. During that window, women accumulated costs from misdiagnosed or undertreated conditions. Early identification and treatment could shift a meaningful portion of those expenditures to lower-cost, more effective interventions.

Workforce Participation and Career Trajectory Effects

Perimenopause does not merely affect daily productivity. It affects career trajectories. Women in their late 40s and early 50s are typically at peak earning and leadership potential, and symptom burden during this window can permanently alter earnings curves.

Job Exit and Hour Reduction

The Mayo Clinic 2023 study found that 13.4% of women reduced working hours and 10.9% exited employment specifically because of menopause symptoms [1]. A separate UK Fawcett Society survey of 4,000 women found that 1 in 10 women over 45 had left a job because of menopause symptoms, with a further 1 in 5 having moved to a less demanding role [10]. These exits occur precisely when women are most likely to move into senior positions, widening the gender leadership gap through a mechanism distinct from overt discrimination.

The Long-Term Earnings Impact

Women who reduce hours or exit the workforce during perimenopause face compounding losses: immediate wage reduction, diminished pension accrual, and foregone promotions. A 2023 report from the Menopause Society estimated that U.S. Women collectively forgo $26.6 billion in lifetime earnings due to menopause-related workforce disruption [9]. That figure covers only the wage component and excludes retirement savings shortfalls.

Employer Costs Beyond Absenteeism

Employers bear turnover costs when symptomatic women exit. Replacing a mid-career employee costs an estimated 50 to 200% of annual salary according to SHRM benchmarks. When menopause-driven exits are included in attrition models, the employer-side cost of unmanaged perimenopause becomes substantial, though few companies track it explicitly.

The Cost-Effectiveness of Treating Perimenopausal Symptoms

Treating perimenopause is not simply a quality-of-life decision. It is an economic one. Evidence from clinical trials and pharmacoeconomic models consistently shows that effective treatment reduces total costs.

Menopausal Hormone Therapy

Menopausal hormone therapy (MHT) remains the most effective treatment for VMS. The 2022 Menopause Society (NAMS) Clinical Practice Statement affirms that MHT is appropriate for healthy women under age 60 or within 10 years of menopause onset, and that the benefits generally outweigh the risks for this group [9]. A pharmacoeconomic model published in Menopause in 2021 estimated that treating moderate-to-severe VMS with low-dose estradiol (0.05 mg transdermal patch) reduced total annual healthcare costs by $1,247 per patient per year compared to untreated women, primarily through lower rates of physician visits, sleep medication use, and antidepressant prescribing [11].

Non-Hormonal Options With Cost Implications

For women who cannot or prefer not to use MHT, the FDA approved fezolinetant (Veozah, 45 mg daily) in May 2023 as the first non-hormonal neurokinin 3 receptor antagonist for moderate-to-severe VMS [12]. Clinical trial data from SKYLIGHT 4 (N=1,830, 52 weeks) showed fezolinetant reduced hot flash frequency by 59% compared to 40% for placebo at week 12 [12]. The drug's list price is approximately $550 per month, making cost-effectiveness dependent on payer negotiation and patient symptom severity.

Paroxetine 7.5 mg (Brisdelle) holds the only other FDA approval specifically for menopause-related VMS among non-hormonal agents [13]. Its effectiveness is more modest than MHT or fezolinetant, with a roughly 33 to 47% reduction in hot flash frequency in key trials, but its generic availability makes it a lower-cost option for mild-to-moderate symptoms.

Return on Investment for Employers

A 2023 analysis in Climacteric modeled the employer return on investment from providing menopause-supportive workplace policies, including flexible scheduling and access to a menopause specialist. The model projected a 5.2:1 return on investment over 3 years, driven by reduced turnover, lower absenteeism, and higher retention of senior female employees [14].

Disparities in Access and Treatment Amplify Economic Harm

Not all women bear equal economic burden. Access to treatment varies substantially by income, insurance status, and race.

Insurance Coverage Gaps

Despite MHT's strong efficacy and safety profile in appropriate candidates, coverage varies across insurance plans. A 2022 analysis of commercial and Medicaid formularies found that transdermal estradiol patches were covered by only 61% of Medicaid plans, and that prior authorization requirements applied in 34% of commercial plans [15]. Women in lower income brackets, who are also more likely to work in jobs with fewer sick-day allowances, face both higher symptom burden and greater barriers to treatment.

Provider Knowledge Gaps

A 2019 survey of 177 internal medicine and family medicine residents published in Menopause found that 70% felt "not at all prepared" or "minimally prepared" to manage menopause [16]. Limited provider training delays diagnosis, increases diagnostic workup costs, and leaves women cycling through specialists before receiving effective care. The Endocrine Society's 2015 Clinical Practice Guideline on menopause explicitly calls for improved clinician education to reduce these delays [17].

Rural and Geographic Access

Women in rural areas face longer travel times to OB-GYN or menopause specialist practices. Telehealth expansion during and after the COVID-19 pandemic has partially bridged this gap. A 2022 retrospective review found that telehealth menopause consultations achieved equivalent symptom-control outcomes to in-person visits at 12 weeks, with significantly higher patient-reported satisfaction for convenience [18].

What Policymakers and Health Systems Can Do

The economic data make a clear case for systemic action. Several concrete interventions have evidence behind them.

Standardized Perimenopause Screening

The Menopause Society recommends that clinicians proactively assess perimenopausal symptoms during routine visits for women aged 40 and older, rather than waiting for patients to raise the topic [9]. Standardized symptom tools like the Menopause Rating Scale (MRS) or the Greene Climacteric Scale take under 5 minutes to complete and have been validated in large multinational cohorts [19].

Workplace Accommodation Policies

The UK's Faculty of Occupational Medicine published guidance in 2016 recommending that employers implement temperature control, access to cold water, flexible scheduling, and non-judgmental disclosure pathways for menopausal employees [20]. Employers who implemented these policies in a subsequent UK pilot reported a 43% reduction in menopause-related sick leave over 12 months.

Coverage Mandates for MHT

Requiring coverage of FDA-approved MHT without prior authorization for women meeting guideline criteria would reduce out-of-pocket costs and increase treatment uptake. Given the pharmacoeconomic data showing $1,247 annual cost savings per treated patient, payers operating at scale would likely see net savings within two years of expanded coverage [11].

Clinical Takeaway: Connecting the Economic Evidence to Patient Care

The economic burden of perimenopause is not abstract. It shows up in payroll data, insurance claims, and retirement accounts. Clinicians who identify and treat perimenopausal symptoms early, using MHT for appropriate candidates or FDA-approved non-hormonal alternatives for others, directly reduce the productivity losses and healthcare expenditures described in this article.

Women presenting with any combination of irregular cycles, VMS, sleep disruption, mood changes, or cognitive difficulties in their 40s should receive a thorough perimenopausal assessment. The Menopause Society's 2022 Clinical Practice Statement recommends initiating MHT with the lowest effective estrogen dose for the shortest duration consistent with treatment goals, reassessing annually [9]. For transdermal estradiol, the typical starting dose is 0.0375 to 0.05 mg per day, titrated based on symptom response at 8 to 12 weeks.

Untreated, the average symptomatic perimenopausal woman loses the equivalent of 3.1 workdays per year to absenteeism alone, before accounting for presenteeism, career-related decisions, or long-term earnings trajectories [1].